PMID- 36105173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220917
IS  - 2214-0883 (Electronic)
IS  - 2095-1779 (Print)
IS  - 2214-0883 (Linking)
VI  - 12
IP  - 4
DP  - 2022 Aug
TI  - Human islet amyloid polypeptide: A therapeutic target for the management of type 
      2 diabetes mellitus.
PG  - 556-569
LID - 10.1016/j.jpha.2022.04.001 [doi]
AB  - Type 2 diabetes mellitus (T2DM) and other metabolic disorders are often silent 
      and go unnoticed in patients because of the lack of suitable prognostic and 
      diagnostic markers. The current therapeutic regimens available for managing T2DM 
      do not reverse diabetes; instead, they delay the progression of diabetes. Their 
      efficacy (in principle) may be significantly improved if implemented at earlier 
      stages. The misfolding and aggregation of human islet amyloid polypeptide (hIAPP) 
      or amylin has been associated with a gradual decrease in pancreatic beta-cell 
      function and mass in patients with T2DM. Hence, hIAPP has been recognized as a 
      therapeutic target for managing T2DM. This review summarizes hIAPP's role in 
      mediating dysfunction and apoptosis in pancreatic beta-cells via induction of 
      endoplasmic reticulum stress, oxidative stress, mitochondrial dysfunction, 
      inflammatory cytokine secretion, autophagy blockade, etc. Furthermore, it 
      explores the possibility of using intermediates of the hIAPP aggregation pathway 
      as potential drug targets for T2DM management. Finally, the effects of common 
      antidiabetic molecules and repurposed drugs; other hIAPP mimetics and peptides; 
      small organic molecules and natural compounds; nanoparticles, nanobodies, and 
      quantum dots; metals and metal complexes; and chaperones that have demonstrated 
      potential to inhibit and/or reverse hIAPP aggregation and can, therefore, be 
      further developed for managing T2DM have been discussed.
CI  - (c) 2022 The Author(s).
FAU - Roham, Pratiksha H
AU  - Roham PH
AD  - Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind, 
      41100, India.
FAU - Save, Shreyada N
AU  - Save SN
AD  - Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind, 
      41100, India.
FAU - Sharma, Shilpy
AU  - Sharma S
AD  - Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind, 
      41100, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220407
PL  - China
TA  - J Pharm Anal
JT  - Journal of pharmaceutical analysis
JID - 101579451
PMC - PMC9463490
OTO - NOTNLM
OT  - Aggregation
OT  - Inhibitor
OT  - Therapeutic target
OT  - Type 2 diabetes mellitus
OT  - hIAPP
EDAT- 2022/09/16 06:00
MHDA- 2022/09/16 06:01
PMCR- 2022/04/07
CRDT- 2022/09/15 02:16
PHST- 2021/10/11 00:00 [received]
PHST- 2022/03/21 00:00 [revised]
PHST- 2022/04/01 00:00 [accepted]
PHST- 2022/09/15 02:16 [entrez]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2022/09/16 06:01 [medline]
PHST- 2022/04/07 00:00 [pmc-release]
AID - S2095-1779(22)00027-2 [pii]
AID - 10.1016/j.jpha.2022.04.001 [doi]
PST - ppublish
SO  - J Pharm Anal. 2022 Aug;12(4):556-569. doi: 10.1016/j.jpha.2022.04.001. Epub 2022 
      Apr 7.